These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12414617)

  • 21. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
    Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
    Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM; Melo JV
    Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
    Pytel D; Wysocki T; Majsterek I
    Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Roots of imatinib resistance: a question of self-renewal?
    Burchert A
    Drug Resist Updat; 2007; 10(4-5):152-61. PubMed ID: 17683977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity.
    Bueno-da-Silva AE; Brumatti G; Russo FO; Green DR; Amarante-Mendes GP
    Cell Death Differ; 2003 May; 10(5):592-8. PubMed ID: 12728257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.
    Nardi V; Raz T; Cao X; Wu CJ; Stone RM; Cortes J; Deininger MW; Church G; Zhu J; Daley GQ
    Oncogene; 2008 Jan; 27(6):775-82. PubMed ID: 17684485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.
    von Bubnoff N; Schneller F; Peschel C; Duyster J
    Lancet; 2002 Feb; 359(9305):487-91. PubMed ID: 11853795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
    Adrián FJ; Ding Q; Sim T; Velentza A; Sloan C; Liu Y; Zhang G; Hur W; Ding S; Manley P; Mestan J; Fabbro D; Gray NS
    Nat Chem Biol; 2006 Feb; 2(2):95-102. PubMed ID: 16415863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imatinib mesylate (STI571)-induced cell edge translocation of kinase-active and kinase-defective Abelson kinase: requirements of myristoylation and src homology 3 domain.
    Fujita A; Shishido T; Yuan Y; Inamoto E; Narumiya S; Watanabe N
    Mol Pharmacol; 2009 Jan; 75(1):75-84. PubMed ID: 18835981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
    Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
    Gambacorti-Passerini C; Barni R; le Coutre P; Zucchetti M; Cabrita G; Cleris L; Rossi F; Gianazza E; Brueggen J; Cozens R; Pioltelli P; Pogliani E; Corneo G; Formelli F; D'Incalci M
    J Natl Cancer Inst; 2000 Oct; 92(20):1641-50. PubMed ID: 11036109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571.
    Tabrizi R; Mahon FX; Cony Makhoul P; Lagarde V; Lacombe F; Berthaud P; Melo JV; Reiffers J; Belloc F
    Leukemia; 2002 Jun; 16(6):1154-9. PubMed ID: 12040447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.
    Roche-Lestienne C; Soenen-Cornu V; Grardel-Duflos N; Laï JL; Philippe N; Facon T; Fenaux P; Preudhomme C
    Blood; 2002 Aug; 100(3):1014-8. PubMed ID: 12130516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.
    le Coutre P; Tassi E; Varella-Garcia M; Barni R; Mologni L; Cabrita G; Marchesi E; Supino R; Gambacorti-Passerini C
    Blood; 2000 Mar; 95(5):1758-66. PubMed ID: 10688835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
    Mow BM; Chandra J; Svingen PA; Hallgren CG; Weisberg E; Kottke TJ; Narayanan VL; Litzow MR; Griffin JD; Sausville EA; Tefferi A; Kaufmann SH
    Blood; 2002 Jan; 99(2):664-71. PubMed ID: 11781252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias.
    Nimmanapalli R; Bhalla K
    Curr Opin Oncol; 2002 Nov; 14(6):616-20. PubMed ID: 12409651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
    Mahon FX; Deininger MW; Schultheis B; Chabrol J; Reiffers J; Goldman JM; Melo JV
    Blood; 2000 Aug; 96(3):1070-9. PubMed ID: 10910924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
    Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
    Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.